Dr Arun J. Sanyal, MD, MBBS, has been a physician-scientist for 25 years and his research has spanned the spectrum of translational science from basic discovery to first in humans and advanced phase clinical trials and regulatory aspects of drug development. These studies have revolved around cirrhosis and its complications and nonalcoholic fatty liver disease, a major complication of obesity.
Dr Sanyal has chaired the NIDDK NASH clinical research network and has been continuously funded for over 20 years. He has also served as chair of the NIH hepatobiliary study section and chair of the division of gastroenterology at VCU. His work in the laboratory has focused on metabolic dysregulation in NASH and cross talk between NASH and alcoholic liver disease. He is particularly interested in how metabolic signals translate in to inflammation and cell stress in NASH.
At a clinical level Dr Sanyal has published a number of studies on the natural history of NASH and has also led multiple large trials for the treatment of NASH. He has specifically published on both the basic and clinical aspects of NASH and cardiovascular risk factors. More recently, he helped create and chair the Liver Forum for NASH which brings the FDA, EMA and other stakeholders together to overcome regulatory barriers to drug development for NASH. Dr Sanyal’s work therefore covers the spectrum of translational science related to NASH.